HYBRID BIOMATERIALS FOR ENGINEERING VASCULAR TISSUES - Biologically-Responsive Hybrid Biomaterials - page 374

[35] Smadja, D.M., et al., “Endothelial Progenitor Cells: Characterization, In Vitro Expansion, and
Prospects for Autologous Cell Therapy,” Cell Biology and Toxicology , Vol. 23, No. 4, 2007,
pp. 223-239.
[36] Aicher, A., M.A. Zeiher, and S. Dimmeler, “Mobilizing Endothelial Progenitor Cells,”
Hypertension , Vol. 45, No. 3, 2005, pp. 321-325.
[37] Adams, V., et al., “Increase of Circulating Endothelial Progenitor Cells in Patients with
Coronary Artery Disease after Exercise-Induced Ischemia,” Arteriosclerosis, Thrombosis and
Vascular Biology , Vol. 24, No. 4, 2004, pp. 684-690.
[38] Strehlow, K., et al., “Estrogen Increases Bone Marrow-Derived Endothelial Progenitor Cell
Production and Diminishes Neointima Formation,” Circulation , Vol. 107, No. 24, 2003, pp.
3059-3065.
[39] Vasa, M., et al., “Increase in Circulating Endothelial Progenitor Cells by Statin Therapy in
Patients with Stable Coronary Artery Disease,” Circulation , Vol. 103, No. 24, 2001, pp.
2885-2890.
[40] Bahlmann, F.H., et al., “Erythropoietin Regulates Endothelial Progenitor Cells,” Blood , Vol.
103, No. 3, 2004, pp. 921-926.
[41] Moore, M.A., et al., Mobilization of Endothelial and Hematopoietic Stem and Progenitor
Cells by Adenovector-Mediated Elevation of Serum Levels of SDF-1, VEGF, and
Angiopoietin-1,” Annals of the New York Academy of Sciences , Vol. 938, 2001, pp. 36-47.
[42] Hill, J.M., et al., “Circulating Endothelial Progenitor Cells, Vascular Function, and
Cardiovascular Risk,” New England Journal of Medicine, Vol. 348, No. 7, 2003, pp. 593-600.
[43] Hristov, M., W. Erl, and P.C. Weber, “Endothelial Progenitor Cells: Mobilization,
Differentiation, and Homing,” Arteriosclerosis, Thrombosis and Vascular Biology , Vol. 23,
No. 7, 2003, pp. 1185-1189.
[44] Hubbell, J.A., “Biomaterials in Tissue Engineering,” Biotechnology (NY) , Vol. 13, No. 6,
1995, pp. 565-576.
[45] van der Flier, A., and A. Sonnenberg, “Function and Interactions of Integrins,” Cell and
Tissue Research , Vol. 305, No. 3, 2001, pp. 285-298.
[46] Kim, B.S., and D.J. Mooney, “Development of Biocompatible Synthetic Extracellular
Matrices for Tissue Engineering,” Trends in Biotechnology , Vol. 16, No. 5, 1998, pp. 224-
230.
[47] Walter, D.H., et al., “Statin Therapy Accelarates Reendothelialization: A Novel Effect
Involving Mobilization and Incorporation of Bone Marrow-Derived Endothelial Progenitor
Cells,” Circulation , Vol. 105, No. 25, 2002, pp. 3017-3024.
[48] Peled, A., et al., “The Chemokine SDF-1 Activates the Integrins LFA-1, VLA-4, and VLA-5
on Immature Human CD34(+) Cells: Role in Transendothelial/Stromal Migration and
Engraftment of NOD/SCID Mice,” Blood , Vol. 95, No. 11, 2000, pp. 3289-3296.
[49] Avci-Adali, M., et al., “New Strategies for In Vivo Tissue Engineering by Mimicry of
Homing Factors for Self-Endothelialisation of Blood Contacting Materials,” Biomaterials ,
Vol. 29, No. 29, 2008, pp. 3936-3945.
[50] Nichols, J.E., and J. Cortiella, “Engineering of a Complex Organ: Progress Toward
Development of a Tissue-Engineered Lung,” Proceedings of the American Thoracic Society ,
Vol. 5, No. 3, 2008, pp. 723-730.
[51] Levy, A.P., N.S. Levy, and M.A. Goldberg, “Hypoxia-Inducible Protein Binding to Vascular
Endothelial Growth Factor mRNA and its Modulation by the Von Hippel-Lindau Protein,”
Journal of Biological Chemistry , Vol. 271, No. 41, 1996, pp. 25492-25497.
[52] Jabbarzadeh, E., and C.F. Abrams, “Strategies to Enhance Capillary Formation Inside
Biomaterials: A Computational Study,” Tissue Engineering , Vol. 13, No. 8, 2007, pp. 2073-
2086.